関連する実験動画
Updated: Feb 14, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.3K
肥満患者のペリアケタブラー骨抜きの合併症の増加は,禁忌ではありません
Jordan Boivin1, Juliana Overbey1, Thomas Ryan2
1Western Michigan Homer Stryker MD School of Medicine, 300 Portage St, Kalamazoo, MI 49007, United States.
Journal of hip preservation surgery
|February 13, 2026
まとめ
周辺頭骨骨切除術 (PAO) を受けている肥満患者は,肥満でない患者と同じような痛みの軽減を経験します. 合併症は肥満の個人により頻繁に見られるが,PAOはアセタブラー・ディスプラジアの痛みを効果的に軽減する.
科学分野:
- 整形外科の手術は,整形外科の手術です.
- 股関節のバイオメカニクス
- 患者のアウトカムに関する研究結果
背景:
- 症状のあるアセタブラー不形成症は,外科的矯正を必要とし,しばしばペリアアセタブラー骨抜き (PAO) を通します.
- 肥満は,より高い合併症リスクが認識されているため,しばしばPAOの禁忌とみなされます.
- PAOを受けた肥満患者と肥満でない患者のアウトカムを比較するデータは限られている.
研究 の 目的:
- 肥満患者が,非肥満患者と比較して,PAO後に比較可能な疼痛緩和とX線改善を達成するかどうかを評価する.
- PAOの後に肥満対非肥満のコホートにおける術後の合併症の発生率を評価する.
- 肥満がアセタブル性不形成症の治療におけるPAOの有効性に対する影響を決定する.
主な方法:
- 12年以上にわたって実施されたPAOの手続きの遡及的レビュー.
- 合併症率,視覚アナログスケール (VAS) の痛みスコア,および肥満と非肥満の患者グループ間の横向中央辺角 (LCEAs) の比較.
- 結果の差異の有意性を判断するための統計分析.
主要な成果:
- 分析された48本のうち15本が肥満患者で,33本が非肥満患者でした.
- 合併症の統計的に有意な増加は,肥満グループ (P=0.04) で観察されました.
- 肥満患者と肥満でない患者のVASスコアやLCEAの有意な差異は,手術前と手術後の両方で見つかりませんでした. また,再運用率は有意な差もなかった (P=0.11).
結論:
- PAOを受けた肥満患者は合併症のリスクが高くなりますが,非肥満患者と同じような痛みの軽減とX線写真の改善を達成します.
- PAOは,肥満患者のアセタブラー発育不全の効果的な治療法であり,痛みの軽減と生活の質の向上につながります.
- 肥満は,比較可能な機能的アウトカムを考慮して,PAOの絶対的な禁忌であるべきではありません.
関連する概念動画
Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
296
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
296
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Increasing Function
403
An increasing function exhibits a rise in output values as input values increase. This behavior is depicted graphically as a curve or line that slopes upward from left to right. Such a function satisfies the condition that if x1 < x2, then f(x1) < f(x2), indicating that the function values grow with increasing inputs. This concept is fundamental in understanding growth trends across various domains, such as population dynamics, financial investments, or resource consumption.The...
403
Hemodialysis II: Procedure and Complications
970
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
970

